Carlyle Group to acquire 20pc stake in Piramal Pharma for Rs 3700 crore

"... CA Clover Intermediate II Investments, an affiliated entity of CAP V Mauritius Ltd, an investment fund managed and advised by affiliated entities of The Carlyle Group Inc has agreed to invest fresh equity capital for a 20 percent stake in Piramal Pharma Ltd," the Ajay Piramal-led company said in a regulatory filing.

Published On 2020-06-28 05:00 GMT   |   Update On 2021-08-14 05:51 GMT
Advertisement

New Delhi: US-based Carlyle Group Inc will pick up a 20 percent stake in Piramal Pharma for around USD 490 million (over Rs 3,700 crore), Piramal Enterprises said on Saturday.

"... CA Clover Intermediate II Investments, an affiliated entity of CAP V Mauritius Ltd, an investment fund managed and advised by affiliated entities of The Carlyle Group Inc has agreed to invest fresh equity capital for a 20 percent stake in Piramal Pharma Ltd," the Ajay Piramal-led company said in a regulatory filing.

Advertisement

The estimated equity capital investment for Carlyle''s 20 percent stake in Piramal Pharma would amount to around USD 490 million, it said.

The final amount of equity investment will depend on the net debt, exchange rate, and performance against the pre-agreed conditions at the time of closing of the deal, it added.

Also Read: Piramal Pharma Solutions Acquires G&W Labs Sellersville Facility

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News